2. (A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and hematopoietic allograft (D) None of above

3. (A) malignant lymphoid neoplasms only (B) benign or malignant lymphoproliferative disorder (C) indolent B-cell lymphomas (D) aggressive B-cell lymphomas only

4. (A) in HSCT allografts are exclusively donor origin (B) in solid organ allogarfts are most donor origin (C) occurring in the HSCT recipients most are limited disease (D) more frequent occurs in the HSCT recipients than in the solid organ transplanted ones

5. (A) universally is Epstein-Barr virus (EBV) positive (B) in children behaves poorer outcome (C) correlates with the destruction of recipient’s immunity and EBV infection/reactivation (D) frequently involves in the bone marrow

6. (A) Anti-viral therapy is effective (B) Preemptive therapy with Rituximab is promising (C) Rutuximab is also effective in CD20- negative patients (D) Reduction of immunosuppression (RIS) is no longer beneficial

9. (A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and hematopoietic allograft (D) None of above

10. (A) malignant lymphoid neoplasms only (B) benign or malignant lymphoproliferative disorder (C) indolent B-cell lymphomas (D) aggressive B-cell lymphomas only

11. (A) in HSCT allografts are exclusively donor origin (B) in solid organ allogarfts are most donor origin (C) occurring in the HSCT recipients most are limited disease (D) more frequent occurs in the HSCT recipients than in the solid organ transplanted ones

12. (A) universally is Epstein-Barr virus (EBV) positive (B) in children behaves poorer outcome (C) correlates with the destruction of recipient’s immunity and EBV infection/reactivation (D) frequently involves in the bone marrow

13. (A) Anti-viral therapy is effective (B) Preemptive therapy with Rituximab is promising (C) Rutuximab is also effective in CD20- negative patients (D) Reduction of immunosuppression (RIS) is no longer beneficial